Restricted accessResearch articleFirst published online 2018-11
Prevalence of Extended-Spectrum Beta-Lactamase and Carbapenemase Genes in Clinical Isolates of Escherichia coli in Myanmar: Dominance of bla NDM-5 and Emergence of bla OXA-181
The increasing trend of Escherichia coli producing extended-spectrum beta-lactamases (ESBLs) and carbapenemases is a global public health concern. In this study, prevalence and molecular characteristics of E. coli harboring ESBL and carbapenemase genes were investigated for 426 isolates derived from various clinical specimens in a teaching hospital in Yangon, Myanmar, for the 1-year period beginning January 2016. A total of 157 isolates (36.9%) were ESBL producers and harbored CTX-M-1 group genes (146 isolates; blaCTX-M-15, blaCTX-M55) or CTX-M-9 group genes (11 isolates; blaCTX-M-14, blaCTX-M-27). Carbapenem resistance was detected in 35 isolates (8.2%), among which 26 isolates had carbapenemase genes encoding NDM-1 (2 isolates), NDM-4 (6 isolates), NDM-5 (14 isolates), NDM-7 (3 isolates), and OXA-181 (2 isolates). blaNDM-5 was identified in phylogenetic groups A, B1, and D isolates belonging to various genotypes (ST101, ST354, ST405, ST410, ST1196) associated with blaTEM-1, blaCTX-M-15, blaOXA-181, blaCMY-2, blaCMY-6, blaCMY-42, qnrB, qnrS, or aac6′-Ib-cr. While two isolates with blaOXA-181 belonged to phylogenetic group A-ST410, one isolate had also blaNDM-5, as well as blaCTX-M-15 and blaCMY-2, and the other harbored blaCMY-42 and aac6′-Ib-cr, showing different resistance patterns. Phylogenetic group B2 isolates examined were classified into mostly ST131 and had solely blaCTX-M-15 or blaCTX-M-27, harboring more virulence factors than other phylogenetic groups. The present study revealed high prevalence of ESBL genes represented by blaCTX-M-15 and dominance of blaNDM-5 among NDM genes, disseminating to various E. coli clones. Notably, carbapenemase gene encoding OXA-181 was first identified in Myanmar, suggesting its spread together with NDM genes.
Get full access to this article
View all access options for this article.
References
1.
GiskeC.G., MonnetD.L., CarsO., and CarmeliY.. 2008. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother., 52:813–821.
2.
PitoutJ.D., and LauplandK.B.. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis., 8:159–166.
3.
NordmannP., DortetL., and PoirelL.. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol. Med., 18:263–272.
4.
BevanE.R., JonesA.M., and HawkeyP.M.. 2017. Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J. Antimicrob. Chemother., 72:2145–2155.
5.
TzouvelekisL.S., MarkogiannakisA., PsichogiouM., TassiosP.T., and DaikosG.L.. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev., 25:682–707.
6.
YangQ., WangH., SunH., ChenH., XuY., and ChenM.. 2010. Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China. Antimicrob. Agents Chemother., 54:573–577.
7.
DortetL., PoirelL., and NordmannP.. 2014. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res. Int., 2014:249856.
8.
MyatT.O., PrasadN., ThinnK.K., WinK.K., HtikeW.W., ZinK.N., MurdochD.R., and CrumpJ.A.. 2014. Bloodstream infections at a tertiary referral hospital in Yangon, Myanmar. Trans. R. Soc. Trop. Med. Hyg., 108:692–698.
9.
MyatT.O., HannawayR.F., ZinK.N., HtikeW.W., WinK.K., CrumpJ.A., MurdochD.R., and UssherJ.E.. 2017. ESBL- and carbapenemase-producing Enterobacteriaceae in patients with bacteremia, Yangon, Myanmar, 2014. Emerg. Infect. Dis., 23:857–859.
10.
SugawaraY., AkedaY., SakamotoN., TakeuchiD., MotookaD., NakamuraS., HagiyaH., YamamotoN., NishiI., YoshidaH., OkadaK., ZinK.N., AyeM.M., TonomoK., and HamadaS.. 2017. Genetic characterization of blaNDM-harboring plasmids in carbapenem-resistant Escherichia coli from Myanmar. PLoS One, 12:e0184720.
11.
Clinical and Laboratory Standards Institute (CLSI). 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement, M100-S24. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA.
12.
MonsteinH.J., Ostholm-BalkhedA., M.V.Nilsson, NilssonM., DornbuschK., and NilssonL.E.. Multiplex PCR amplification assay for the detection of blaSHV, blaTEM and blaCTX-M genes in Enterobacteriaceae. APMIS, 115:1400–1408.
13.
XuL., EnsorV., GossainS., NyeK., and HawkeyP.. 2005. Rapid and simple detection of blaCTX-M genes by multiplex PCR assay. J. Med. Microbiol., 54:1183–1187.
14.
QueenanA.M., and BushK.. 2007. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev., 20:440–458.
15.
PoirelL., WalshT.R., CuvillierV., and NordmannP.. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis., 70:119–123.
16.
ÖsterbladM., KirveskariJ., HakanenA.J., TissariP., VaaraM., and JalavaJ.. 2012. Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008–11). J. Antimicrob. Chemother., 67:2860–2864.
17.
Pérez-PérezF.J., and HansonN.D.. 2002. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol., 40:2153–2162.
18.
ClermontO., BonacorsiS., and BingenE.. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol., 66:4555–4558.
19.
CiesielczukH., HornseyM., ChoiV., WoodfordN., and WarehamD.W.. 2013. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. J. Med. Microbiol., 62:1823–1827.
20.
ClermontO., LavollayM., VimontS., DeschampsC., ForestierC., BrangerC., DenamurE., and ArletG.. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother., 61:1024–1028.
21.
BauerR.J., ZhangL., FoxmanB., SiitonenA., JantunenM.E., SaxenH., and MarrsC.F.. 2002. Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection-usp, iha, and iroN (E. coli). J. Infect. Dis., 185:1521–1524.
22.
BidetP., BonacorsiS., ClermontO., De MontilleC., BrahimiN., and BingenE.. 2005. Multiple insertional events, restricted by the genetic background, have led to acquisition of pathogenicity island IIJ96-like domains among Escherichia coli strains of different clinical origins. Infect. Immun., 73:4081–4087.
23.
JohnsonJ.R., and StellA.L.. 2000. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis., 181:261–272.
24.
JohnsonJ.R., RussoT.A., TarrP.I., CarlinoU., BilgeS.S., VaryJ.C.Jr., and StellA.L.. 2000. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN (E. coli), among Escherichia coli isolates from patients with urosepsis. Infect. Immun., 68:3040–3047.
25.
JohnsonJ.R., GajewskiA., LesseA.J., and RussoT.A.. 2003. Extraintestinal pathogenic Escherichia coli as a cause of invasive nonurinary infections. J. Clin. Microbiol., 41:5798–5802.
26.
JohnsonJ.R., JohnstonB., KuskowskiM.A., NougayredeJ.P., and OswaldE.. 2008. Molecular epidemiology and phylogenetic distribution of the Escherichia coli pks genomic island. J. Clin. Microbiol., 46:3906–3911.
27.
Pilarczyk-ZurekM., ChmielarczykA., GosiewskiT., TomusiakA., AdamskiP., Zwolinska-WcisloM., MachT., HeczkoP.B., and StrusM.. 2013. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol. 13:61 DOI: 10.1186/1471-230X-13-61.
28.
RestieriC., GarrissG., LocasM.C., and DozoisC.M.. 2007. Autotransporter-encoding sequences are phylogenetically distributed among Escherichia coli clinical isolates and reference strains. Appl. Environ. Microbiol., 73:1553–1562.
29.
YamamotoT., and EcheverriaP.. 1996. Detection of the enteroaggregative Escherichia coli heat-stable enterotoxin 1 gene sequences in enterotoxigenic E. coli strains pathogenic for humans. Infect. Immun., 64:1441–1445.
30.
WirthT., FalushD., LanR., CollesF., MensaP., WielerL.H., KarchH., ReevesP.R., MaidenM.C., OchmanH., and AchtmanM.. 2006. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol. Microbiol., 60:1136–1151.
31.
SuwantaratN., and CarrollK.C.. 2016. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob. Resist. Infect. Control, 5:15.
32.
Nicolas-ChanoineM.H., BlancoJ., Leflon-GuiboutV., DemartyR., AlonsoM.P., CaniçaM.M., ParkY.J., LavigneJ.P., PitoutJ., and JohnsonJ.R.. 2008. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother., 61:273–281.
33.
RogersB.A., SidjabatH.E., and PatersonD.L.. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother., 66:1–14.
34.
ChaM.K., KangC.I., KimS.H., ThamlikitkulV., SoT.M., HaY.E., ChungD.R., PeckK.R., and SongJ.H.. 2017. Emergence and dissemination of ST131 Escherichia coli isolates among patients with hospital-acquired pneumonia in Asian countries. Microb. Drug Resist., 23:79–82.
35.
BonnetR., ReculeC., BaraducR., ChanalC., SirotD., De ChampsC., and SirotJ.. 2003. Effect of D240G substitution in a novel ESBL CTX-M-27. J. Antimicrob. Chemother., 52:29–35.
36.
MatsumuraY., JohnsonJ.R., YamamotoM., NagaoM., TanakaM., TakakuraS., and IchiyamaS.; Kyoto–Shiga Clinical Microbiology Study Group; Kyoto-Shiga Clinical Microbiology Study Group. 2015. CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic. J. Antimicrob. Chemother., 70:1639–1649.
37.
ZhongY.M., LiuW.E., LiangX.H., LiY.M., JianZ.J., and HawkeyP.M.. 2015. Emergence and spread of O16-ST131 and O25b-ST131 clones among faecal CTX-M-producing Escherichia coli in healthy individuals in Hunan Province, China. J. Antimicrob. Chemother., 70:2223–2227.
38.
BirgyA., LevyC., BidetP., ThollotF., DerkxV., BéchetS., Mariani-KurkdjianP., CohenR., and BonacorsiS.. 2016. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J. Antimicrob. Chemother., 71:2949–2956.
39.
MatsumuraY., PitoutJ.D., GomiR., MatsudaT., NoguchiT., YamamotoM., PeiranoG., DeVinneyR., BradfordP.A., MotylM.R., TanakaM., NagaoM., TakakuraS., and IchiyamaS.. 2016. Global Escherichia coli sequence type 131 clade with blaCTX-M-27 gene. Emerg. Infect. Dis., 22:1900–1907.
40.
GhoshH., DoijadS., FalgenhauerL., FritzenwankerM., ImirzaliogluC., and ChakrabortyT.. 2017. blaCTX-M-27-encoding Escherichia coli sequence type 131 lineage C1-M27 clone in clinical isolates, Germany. Emerg. Infect. Dis., 23:1754–1756.
41.
TolemanM.A., BugertJ.J., and NizamS.A.. 2015. Extensively drug-resistant New Delhi metallo-β-lactamase-encoding bacteria in the environment, Dhaka, Bangladesh, 2012. Emerg. Infect. Dis., 21:1027–1030.
42.
RanjanA., ShaikS., MondalA., NandanwarN., HussainA., SemmlerT., KumarN., TiwariS.K., JadhavS., WielerL.H., and AhmedN.. 2016. Molecular epidemiology and genome dynamics of New Delhi metallo-β-lactamase-producing extraintestinal pathogenic Escherichia coli strains from India. Antimicrob. Agents Chemother., 60:6795–6805.
43.
RahmanM., ShuklaS.K., PrasadK.N., OvejeroC.M., PatiB.K., TripathiA., SinghA., SrivastavaA.K., and Gonzalez-ZornB.. 2014. Prevalence and molecular characterisation of New Delhi metallo-β-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India. Int. J. Antimicrob. Agents, 44:30–37.
44.
NakanoR., NakanoA., HikosakaK., KawakamiS., MatsunagaN., AsaharaM., IshigakiS., FurukawaT., SuzukiM., ShibayamaK., and OnoY.. 2014. First report of metallo-β-lactamase NDM-5-producing Escherichia coli in Japan. Antimicrob. Agents Chemother., 58:7611–7612.
45.
ParkM., ParkS.D., LeeM.H., KimS.H., LimK., LeeG., WooH.J., KimH.W., YangJ.Y., EomY.B., MoonC., UhY., and KimJ.B.. 2016. The first report of NDM-5-producing uropathogenic Escherichia coli isolates in South Korea. Diagn. Microbiol. Infect. Dis., 85:198–199.
46.
ChenD., GongL., WalshT.R., LanR., WangT., ZhangJ., MaiW., NiN., LuJ., XuJ., and LiJ.. 2016. Infection by and dissemination of NDM-5-producing Escherichia coli in China. J. Antimicrob. Chemother., 71:563–565.
47.
WailanA.M., PatersonD.L., CafferyM., SowdenD., and SidjabatH.E.. 2015. Draft genome sequence of NDM-5-producing Escherichia coli sequence type 648 and genetic context of blaNDM-5 in Australia. Genome Announc., 3:e00194-15.
48.
MediavillaJ.R., PatrawallaA., ChenL., ChavdaK.D., MathemaB., VinnardC., DeverL.L., and KreiswirthB.N.. 2016. Colistin- and carbapenem-resistant Escherichia coli harboring mcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. MBio, 7:e01191-16.
49.
HornseyM., PheeL., and WarehamD.W.. 2011. A novel variant, NDM-5, of the New Delhi metallo-β-lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom. Antimicrob. Agents Chemother., 55:5952–5954.
50.
BitarI., PiazzaA., GaiarsaS., VillaL., PedroniP., OlivaE., NucleoE., PaganiL., CarattoliA., and MigliavaccaR.. 2017. ST405 NDM-5 producing Escherichia coli in Northern Italy: the first two clinical cases. Clin. Microbiol. Infect., 23:489–490.
51.
SassiA., LoucifL., GuptaS.K., DekhilM., ChettibiH., and RolainJ.M.. 2014. NDM-5 carbapenemase-encoding gene in multidrug-resistant clinical isolates of Escherichia coli from Algeria. Antimicrob. Agents Chemother., 58:5606–5608.
52.
HuX., XuX., WangX., XueW., ZhouH., ZhangL., MaQ., ZhaoR., LiG., LiP., ZhangC., ShiY., WangJ., JiaL., HaoR., WangL., ZouD., LiuX., QiuS., SongH., and SunY.. 2017. Diversity of New Delhi metallo-beta-lactamase-producing bacteria in China. Int. J. Infect. Dis., 55:92–95.
53.
NordmannP., BoulangerA.E., and PoirelL.. 2012. NDM-4 metallo-β-lactamase with increased carbapenemase activity from Escherichia coli. Antimicrob. Agents Chemother., 56:2184–2186.
54.
ZhuY.Q., ZhaoJ.Y., XuC., ZhaoH., JiaN., and LiY.N.. 2016. Identification of an NDM-5-producing Escherichia coli sequence type 167 in a neonatal patient in China. Sci. Rep., 6:29934.
55.
GöttigS., HamprechtA.G., ChristS., KempfV.A., and WichelhausT.A.. 2013. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo-β-lactamase with increased carbapenemase activity. J. Antimicrob. Chemother., 68:1737–1740.
56.
MushtaqS., IrfanS., SarmaJ.B., DoumithM., PikeR., PitoutJ., LivermoreD.M., and WoodfordN.. 2011. Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. J. Antimicrob. Chemother., 66:2002–2005.
57.
JakobsenL., HammerumA.M., HansenF., and Fuglsang-DamgaardD.. 2014. An ST405 NDM-4-producing Escherichia coli isolated from a Danish patient previously hospitalized in Vietnam. J. Antimicrob. Chemother., 69:559–560.
58.
QinS., ZhouM., ZhangQ., TaoH., YeY., ChenH., XuL., XuH., WangP., and FengX.. 2016. First identification of NDM-4-producing Escherichia coli ST410 in China. Emerg. Microbes Infect., 5:e118.
59.
CuzonG., BonninR.A., and NordmannP.. 2013. First identification of novel NDM carbapenemase, NDM-7, in Escherichia coli in France. PLoS One, 8:e61322.
60.
PálT., GhazawiA., DarwishD., VillaL., CarattoliA., HashmeyR., AldeesiZ., JamalW., RotimiV., Al-JardaniA., Al-AbriS.S., and Á. Sonnevend. 2017. Characterization of NDM-7 carbapenemase-producing Escherichia coli isolates in the Arabian Peninsula. Microb. Drug Resist., 23:871–878.
61.
van der Mee-MarquetN., DieneS.M., ChopinF., GoudeauA., and FrançoisP.. 2016. Enigmatic occurrence of NDM-7 enzyme in the community. Int. J. Antimicrob. Agents, 47:505–507.
62.
CastanheiraM., DeshpandeL.M., MathaiD., BellJ.M., JonesR.N., and MendesR.E.. 2011. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. Antimicrob. Agents Chemother., 55:1274–1278.
63.
BalmM.N., LaM.V., KrishnanP., JureenR., LinR.T., and TeoJ.W.. 2013. Emergence of Klebsiella pneumoniae co-producing NDM-type and OXA-181 carbapenemases. Clin. Microbiol. Infect., 19:E421–E423.
64.
ChoS.Y., HuhH.J., BaekJ.Y., ChungN.Y., RyuJ.G., KiC.S., ChungD.R., LeeN.Y., and SongJ.H.. 2015. Kbsiella pneumoniae co-producing NDM-5 and OXA-181 carbapenemases, South Korea. Emerg. Infect. Dis., 21:1088–1089.
65.
LiuY., FengY., WuW., XieY., WangX., ZhangX., ChenX., and ZongZ.. 2015. First report of OXA-181-producing Escherichia coli in China and characterization of the isolate using whole-genome sequencing. Antimicrob. Agents Chemother., 59:5022–5025.
66.
GamalD., Fernández-MartínezM., El-DefrawyI., Ocampo-SosaA.A., and Martínez-MartínezL.. 2016. First identification of NDM-5 associated with OXA-181 in Escherichia coli from Egypt. Emerg. Microbes Infect., 5:e30.
67.
HasassriM.E., BoyceT.G., NorganA., CunninghamS.A., JeraldoP.R., WeissmanS., PatelR., BanerjeeR., PogueJ.M., and KayeK.S.. 2016. An immunocompromised child with bloodstream infection caused by two Escherichia coli strains, one harboring NDM-5 and the other harboring OXA-48-like carbapenemase. Antimicrob. Agents Chemother., 60:3270–3275.
68.
LunhaK., ChanawongA., LulitanondA., WilailuckanaC., CharoensriN., WonglakornL., SaenjamlaP., ChaimaneeP., AngkititrakulS., and ChetchotisakdP.. 2016. High-level carbapenem-resistant OXA-48-producing Klebsiella pneumoniae with a novel OmpK36 variant and low-level, carbapenem-resistant, non-porin-deficient, OXA-181-producing Escherichia coli from Thailand. Diagn. Microbiol. Infect. Dis., 85:221–226.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
